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Immune Checkpoint Axes Are 
Dysregulated in Patients With 
Alcoholic Hepatitis
Wei Li,1* Ying Xia,1-3* Jing Yang,1,3 Haitao Guo,1 Guoqing Sun,1 Arun J. Sanyal,4 Vijay H. Shah ,5 Yongliang Lou,3 
Xiaoqun Zheng,2,3 Naga Chalasani,6 and Qigui Yu1
Alcoholic hepatitis (AH) is a severe inflammatory liver disease that develops in some heavy drinkers. The immune 
system in patients with AH is hyperactive and yet dysfunctional. Here, we investigated whether this immune-dysreg-
ulated state is related to the alcoholic impact on immune checkpoints (ICPs). We used multiplex immunoassays and 
enzyme-linked immunosorbent assay to quantify plasma levels of 18 soluble ICPs (sICPs) from 81 patients with AH, 
65 heavy drinkers without liver diseases (HDCs), and 39 healthy controls (HCs) at baseline, 33 patients with AH and 
32 HDCs at 6-month follow-up, and 18 patients with AH and 29 HDCs at 12-month follow-up. We demonstrated 
that baseline levels of 6 sICPs (soluble T-cell immunoglobulin and mucin domain 3 [sTIM-3], soluble cluster of dif-
ferentiation [sCD]27, sCD40, soluble Toll-like receptor-2 [sTLR-2], soluble herpesvirus entry mediator [sHVEM], 
and soluble lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells 
[sLIGHT])  were up-regulated, while 11 sICPs (soluble B- and T-lymphocyte attenuator [sBTLA], sCD160, solu-
ble cytotoxic T-lymphocyte-associated protein 4 [sCTLA-4], soluble lymphocyte-activation gene 3 [sLAG-3], soluble 
programmed death 1 [sPD-1], sPD ligand 1 [sPD-L1], sCD28, soluble glucocorticoid-induced tumor necrosis fac-
tor receptor-related protein [sGITR], sGITR ligand [sGITRL], sCD80, and inducible T-cell costimulator [sICOS]) 
were down-regulated in patients with AH compared to HDCs. The up-regulated sICPs except sLIGHT and down- 
regulated sCD80, sCD160, sCTLA-4, and sLAG-3 correlated positively or negatively with AH disease severity, bacte-
rial translocation, and inflammatory factors. At follow-up, abstinent patients with AH still had higher levels of several 
sICPs compared to HDCs. We also compared expression of 10 membrane-bound ICPs (mICPs) on peripheral blood 
mononuclear cells (PBMCs) from patients with AH and HCs by flow cytometry and found that several mICPs were 
dysregulated on blood cells from patients with AH. The function and regulation of sICPs and mICPs were studied 
using PBMCs from patients with AH and HCs. Recombinant sHVEM affected tumor necrosis factor (TNF)-α and 
interferon-γ production by T cells from patients with AH and HCs. Conclusion: Both sICPs and mICPs were dysregu-
lated in patients with AH, and alcohol abstinence did not fully reverse these abnormalities. The HVEM axis plays a 
role in regulating T-cell function in patients with AH. (Hepatology Communications 2020;4:588-605).
Alcoholic hepatitis (AH) is a severe inflamma-tory liver disease that develops in 10%-35% of chronic heavy drinkers. Although the exact 
trigger for development of AH is still unclear, alco-
hol-induced translocation of gut bacteria and bacterial 
components into the liver and blood and subsequent 
activation of liver-resident macrophages (Kupffer cells) 
and other immune and nonimmune cells play a crit-
ical role in the initiation and progression of AH.(1-3) 
Patients with AH have elevated levels of a wide range 
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and T-lymphocyte attenuator; CD, cluster of differentiation; CRP, C-reactive protein; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DMSO, 
dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; GITR, glucocorticoid-induced tumor necrosis factor receptor-related protein; 
GITRL, glucocorticoid-induced tumor necrosis factor receptor-ligand; HC, healthy control; HDC, heavy drinking control; HVEM, herpesvirus entry 
mediator; HVEM-his, his-tagged recombinant human herpesvirus entry mediator; ICOS, inducible T-cell costimulator; ICP, immune checkpoint; 
IFN, interferon; IgG, immunoglobulin G; IL, interleukin; LAG-3, lymphocyte-activation gene 3; LBP, lipopolysaccharide-binding protein; LIGHT, 
lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells; LPS, lipopolysaccharide; LT-α, lymphotoxin-
alpha; m, membrane bound; mDF, Maddrey’s discriminant function; MELD, Model for End-Stage Liver Disease; MMP, matrix metalloproteinase; 
NK cell, natural killer; NKT, cell natural killer T cell; ns, not signif icant; PBMC, peripheral blood mononuclear cell; PBS, phosphate-buffered saline; 
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of proinflammatory factors, such as interleukin-8 
(IL-8) and tumor necrosis factor alpha (TNF-α), and 
their immune cells are highly dysregulated, which is 
characterized by immune hyperactivation, exhaustion, 
and dysfunction.(1,3-6)
Immune homeostasis, which is critical for main-
taining immune self-tolerance and preventing over-
exuberant immune responses, is regulated by multiple 
factors, including balanced signals from a network of 
immune costimulatory and coinhibitory receptors/
ligands, collectively known as immune checkpoints 
(ICPs). More than 20 ICP pathways consisting of ICP 
receptors and their ligands have been identified, such 
as the costimulatory cluster of differentiation (CD)28/
CD80/CD86 pathway and the inhibitory path-
ways of cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4)/CD80/CD86 and programmed death 1 
(PD-1)/PD ligand 1 (PD-L1)/PD-L2. Among the 
ICPs, herpesvirus entry mediator (HVEM) serves 
as a shared receptor or ligand for stimulatory and 
inhibitory ligands/receptors, including lymphotoxin- 
alpha (LT-α), lymphotoxin-like inducible protein that 
competes with glycoprotein D for herpes virus entry 
on T cells (LIGHT), B- and T-lymphocyte attenu-
ator (BTLA), and CD160. HVEM and its ligands 
are expressed on both hematopoietic and nonhemato-
poietic cells. Ligation of HVEM with LT-α, LIGHT, 
BTLA, or CD160 stimulates immune responses, 
while as a ligand, HVEM triggers inhibitory signaling 
in BTLA+ and CD160+ T cells but stimulatory sig-
naling in CD160+ natural killer (NK) cells.(7,8) Thus, 
HVEM mediates bidirectional signaling and serves as 
a molecular switch between stimulatory and inhibitory 
signaling, thereby playing a unique role in immune 
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homeostasis. Currently, the regulation and function of 
HVEM in AH pathogenesis is not known.
Different ICPs are expressed at different levels and 
at distinct checkpoints to fine-tune immune responses. 
However, chronic inflammation in the settings of can-
cer, autoimmunity, chronic infection, and sepsis leads 
to persistent hyperexpression of multiple coinhibitory 
ICPs and subsequent functional paralysis/exhaustion 
of the immune system. Blockade of the immunosup-
pressive CTLA-4, PD-1, and PD-L1 pathways with 
ICP inhibitors has been successfully used to restore and 
enhance the antitumor activity of cytotoxic T lympho-
cytes.(9,10) Targeting the main inhibitory ICPs (CTLA-
4, lymphocyte-activation gene 3 [LAG-3], PD-1, and 
T-cell immunoglobulin and mucin domain 3 [TIM-3]) 
pathways has also been explored for therapeutic inter-
vention in inflammatory diseases.(11,12) Recently, ex vivo 
blockage of PD-1 and TIM-3 has been shown to restore 
functions of immune cells from patients with AH.(6)
ICP molecules also exist in soluble forms. Similar to 
membrane-bound ICPs (mICPs), soluble ICPs (sICPs) 
are also present in normal physiologic conditions and 
are highly dysregulated in patients with cancer or var-
ious inflammatory diseases.(12-16) Soluble ICPs can be 
generated through either alternative messenger RNA 
(mRNA) splicing and secretion, extracellular release 
of membrane-bound receptors from exosomes, or 
protease-mediated shedding from mICPs by actions 
of matrix metalloproteinases (MMPs). Some, if 
not all, sICPs exhibit biological functions as decoy 
receptors/ligands for mICPs or as agonists to posi-
tively or negatively regulate immune responses.(16-18) 
Levels of circulating sICPs are often elevated in can-
cer and inflammatory diseases, serving as promising 
prognostic and/or predictive biomarkers.(16)
Currently, there are no systematic studies of either 
mICPs or sICPs in patients with AH. Given that 
ICPs are the key regulators of immune responses 
and that patients with AH are in a highly immune- 
dysregulated state, ICP axes are likely dysregulated 
in patients with AH. To this end, we performed 
comprehensive studies of mICPs and sICPs in the 
peripheral blood of a large cohort of patients with 
AH and matched heavy drinkers without liver disease 
(HDCs) as well as healthy controls (HCs). We also 
studied the effects of long-term alcohol abstinence on 
the regulation of ICPs and the relationships of ICP 
profiles with patient clinical parameters and plasma 
levels of bacterial translocation-associated markers, 
inflammatory cytokines/chemokines, and MMPs. In 
addition, we used peripheral blood cells to study the 
mechanisms underlying the molecular origin, regula-
tion, and function of ICPs. We found that both sICPs 
and mICPs were highly dysregulated in patients with 
AH and that alcohol abstinence did not fully reverse 
these abnormalities.
Participants and Methods
Human suBJeCts anD BlooD 
samples
The subjects with heavy alcohol consumption 
(81 patients with AH and 65 HDCs at baseline, 
33 patients with AH and 32 HDCs at 6-month fol-
low-up, and 18 patients with AH and 29 HDCs at 
12-month follow-up) were part of the multicenter 
prospective Translational Research and Evolving 
Alcoholic Hepatitis Treatment (TREAT) consortium 
(NCT02 172898), as described in our previous stud-
ies.(4,19) HDCs were individuals with a comparable 
history of alcohol consumption but had no overt evi-
dence of liver disease. Thirty-nine healthy volunteers 
were included as HCs. Peripheral blood was obtained 
from these study subjects and separated into plasma 
and peripheral blood mononuclear cells (PBMCs). 
This study was approved by the Institutional 
Review Boards at Indiana University School of 
Medicine, Mayo Clinic, and Virginia Commonwealth 
University. All participants provided written informed 
consent.
multipleX immunoassays
The Human Immuno-Oncology Checkpoint 
Protein Panel (MilliporeSigma, Burlington, MA) was 
used to simultaneously measure plasma concentrations 
of 16 sICPs (sBTLA, sCD27, sCD28, sCD40, sCD80/
B7-1, sCD86/B7-2, sCTLA-4, soluble glucocorticoid- 
induced tumor necrosis factor receptor-related protein 
(sGITR), sGITR ligand (sGITRL), sHVEM, solu-
ble inducible T-cell costimulator (sICOS), sLAG-3, 
sPD-1, sPD-L1, sTIM-3, and soluble Toll-like recep-
tor 2 [sTLR-2]). Human MMP Magnetic Panel 2 
(MilliporeSigma) was used to simultaneously quan-
tify plasma levels of five MMPs, including MMP1, 
MMP2, MMP7, MMP9, and MMP10.
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enZyme-linKeD 
immunosoRBent assays
Plasma levels of sCD160 and sLIGHT were 
quantified using the Human CD160 Matched 
enzyme-linked immunosorbent assay (ELISA) 
Antibody Pair Set (Sino Biological, Beijing, China) 
and the Human LIGHT Duoset ELISA Kit (R&D 
Systems, Minneapolis, MN), respectively. Plasma 
levels of the endotoxin lipopolysaccharide (LPS), 
soluble LPS-binding protein (sLBP), soluble CD14 
(sCD14), and soluble CD163 (sCD163) were 
used as surrogate markers for bacterial transloca-
tion from the gut to the systemic circulation. LPS 
amounts were determined as described.(4) Plasma 
levels of sLBP, sCD14, and sCD163 were quanti-
fied using the Human LBP DuoSet ELISA kit and 
the Human CD14 and CD163 Quantikine kits 
(R&D Systems), respectively. Levels of sHVEM in 
cell-free supernatant of in vitro monocyte cultures 
were determined using the Human HVEM DuoSet 
ELISA kit (R&D Systems).
Cell CultuRe anD IN VITRO 
stimulation
To determine the effect of LPS and alcohol on 
sHVEM production and mHVEM expression on 
the surface of monocytes and B cells, 0.4  ×  106 
PBMCs or purified monocytes using Human CD14 
Microbeads (Miltenyi Biotec, Auburn, CA) from 
HCs were treated with 200 ng/mL LPS and/or 
250 mM ethanol for 24 hours. Cell-free supernatant 
and cells were used for ELISA and flow cytometric 
analysis to determine the expression of sHVEM and 
mHVEM, respectively.
mmp CleaVage anD 
BiologiCal FunCtion oF 
sHVem
To test the effect of MMPs on shedding of 
HVEM from monocytes, purified CD14+ monocytes 
were pretreated with GM6001 (MilliporeSigma), 
a broad-spectrum MMP inhibitor, at 20 μM or 
dimethyl sulfoxide (DMSO) as the vehicle control 
for 30 minutes, followed by LPS and alcohol treat-
ment for 24 hours. The expressions of sHVEM and 
mHVEM were measured as described above.
To test the effect of sHVEM on T-cell function, 
0.2 × 106 PBMCs from patients with AH and HCs 
were pretreated with 5 μg/mL his-tagged recombi-
nant human HVEM (HVEM-his; Sino Biological) 
or phosphate-buffered saline (PBS) for 30 minutes at 
37°C, followed by treatment with soluble anti-CD3/
anti-CD28 antibodies (1 μg/mL each; both from 
Biolegend, Diego, CA) for 20 hours. Brefeldin A was 
added for the last 6 hours of stimulation. Cells were 
subjected to intracellular staining (ICS) of cytokines. 
PBMCs were also pretreated with 5 μg/mL recom-
binant human HVEM-Fc fusion protein (R&D 
Systems) or human immunoglobulin G-1 (hIgG1) 
control (BioLegend; San Diego, CA) before stimula-
tion with anti-CD3/anti-CD28 antibodies.
FloW CytometRiC analysis
To stain mICPs on the subsets of peripheral 
blood immune cells, PBMCs from patients with 
AH and HCs were incubated with fixable viability 
dye (Thermo Fisher Scientific, Cincinnati, OH), 
followed by staining with fluorochrome-conjugated 
antibodies against cell lineage markers (CD3, CD4, 
CD14, CD19, and CD56) and 10 ICPs (BTLA, 
CD27, CD40, CD160, CTLA-4, HVEM, LAG-3, 
LIGHT, PD-1, and TIM-3). All antibodies were 
from BioLegend.
For ICS, PBMCs were stained with fixable viabil-
ity dye, followed by fluorochrome-conjugated anti-
bodies against human CD4 and CD8. Subsequently, 
cells were fixed and permeabilized with the Cytofix/
Cytoperm reagents (BD Biosciences, San Jose, CA) 
and stained with antibodies against TNF-α and 
interferon-gamma (IFN-γ) (BioLegend).
statistiCal analysis
Chi-square test was used for comparison between 
groups for categorical variables. Mann-Whitney test 
and Kruskal-Wallis test with Dunn’s corrections were 
used to calculate differences in continuous variables 
between two groups and among three groups in 
cross-sectional analysis, respectively. The linear rela-
tionship between ICPs and clinical or inflammatory 
factors was analyzed using the Spearman correlation 
test. Friedman rank sum test with Dunn’s corrections 
was used to calculate differences in longitudinal anal-
ysis. Cox regression analysis was performed to identify 
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sICPs associated with 90-day mortality. Soluble ICPs 
with P < 0.10 in univariate analysis were entered into 
a multivariate model using the backward elimination 
method to identify independent predictors of 90-day 
mortality. Repeated measures analysis of variance test 
followed by Dunnett’s test was used to compare dif-
ferences in levels of membrane and soluble HVEM 
between the medium group and other in vitro treat-
ment groups. Paired t test was used to compare dif-
ferences in membrane and soluble HVEM between 
DMSO and GM6001 groups and to compare dif-
ferences in cytokine production between HVEM-his 
and PBS groups and between HVEM-Fc and hIgG1. 
P < 0.05 was considered statistically significant.
Results
CHaRaCteRistiCs oF tHe 
stuDy CoHoRt
The demographic and clinical characteristics of 
the study subjects are summarized in Table 1. Age 
and sex distributions were similar among patients 
with AH, HDCs, and HCs at baseline and between 
patients with AH and HDCs at follow-ups. HDCs 
had significantly more drinks than patients with AH 
in the last 30 days before the enrollment and at day 
360. Although baseline total bilirubin and creatinine 
were not different between HDCs and HCs, both 
aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels were higher in HDCs than 
HCs. At enrollment and follow-up, patients with 
AH had higher Model for End-Stage Liver Disease 
(MELD) scores, liver biochemistries (AST, ALT, and 
total bilirubin), and longer prothrombin time than 
HDCs. Forty-eight patients with AH (59%) were 
treated with prednisone alone (n = 33), pentoxifylline 
alone (n  =  2), or both drugs (n  =  13); 14 patients 
with AH died within 3  months after enrollment. 
At follow-up, patients with AH and HDCs drank 
much less and liver biochemistries greatly improved 
but were not normalized in patients with AH and 
remained unchanged for HDCs. For patients who 
achieved complete alcohol abstinence at follow-up, 
MELD score, total bilirubin, AST, and prothrom-
bin time were still higher in patients with AH than 
HDCs (Supporting Table S1).
plasma leVels oF soluBle  
iCps WeRe HigHly 
DysRegulateD in patients 
WitH aH
Plasma levels of 18 sICPs, including 10 stimula-
tory, seven inhibitory, and one dual functional ICPs, 
are summarized in Table 2, Supporting Table S2, 
and Supporting Fig. S1. All 18 sICPs were detect-
able in HCs, indicating that they could play biolog-
ical roles in immune homeostasis under physiologic 
conditions. Compared to HCs and HDCs, patients 
with AH had significantly higher baseline levels of 
two stimulatory sICPs (sCD27 and sCD40), one 
inhibitory sICP (sTIM-3), and the bifunctional 
sHVEM. Patients with AH also had higher baseline 
levels of sLIGHT and sTLR-2 than HDCs. Plasma 
sTIM-3 was the most highly up-regulated sICP in 
patients with AH, followed by sHVEM, sCD40, 
sCD27, sTLR-2, and sLIGHT. Baseline levels 
of the remaining six inhibitory sICPs (sBTLA, 
sCD160, sCTLA-4, sLAG-3, sPD-1, and sPD-L1) 
and five stimulatory sICPs (sCD28, sCD80, sGITR, 
sGITRL, and sICOS) were down-regulated in 
patients with AH, with sICOS and sCD160 among 
the most down-regulated. Plasma sCD86 level 
did not differ among HCs, patients with AH, and 
HDCs. Interestingly, five sICPs were also dysreg-
ulated in HDCs, as sCD40 and sTIM-3 were up- 
regulated while sCD80, sGITRL, and sLIGHT were 
down-regulated relative to HCs. These results sug-
gest that plasma levels of these five sICPs (sCD40, 
sCD80, sGITRL, sICOS, and sTIM-3) could serve 
as sensitive markers for subclinical immune activa-
tion or dysregulation in HDCs.
At follow-up, plasma levels of sICPs tended to 
be normalized in patients with AH but remained 
unchanged in HDCs. However, at 6-month follow-up, 
five out of the six up-regulated sICPs (sCD27, sCD40, 
sHVEM, sTIM-3, and sTLR-2) were still elevated in 
patients with AH whereas all the 11 down-regulated 
sICPs became similarly expressed between patients 
with AH and HDCs. At 12-month follow-up, only 
sTIM-3 remained higher while sCTLA-4 and 
sPD-L1 were still lower in patients with AH com-
pared to HDCs (Table 2; Supporting Table S2). 
Together, our data indicate that plasma levels of sICPs 
were highly dysregulated in patients with AH and 
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that there was an incomplete reversal of those abnor-
malities at follow-up.
assoCiation BetWeen plasma 
leVels oF soluBle iCps anD 
CliniCal paRameteRs in 
patients WitH aH
Five up-regulated sICPs (sCD27, sCD40, sHVEM, 
sTIM-3, and sTLR-2) positively correlated with the 
MELD score, and some also had positive correlations 
with total bilirubin, creatinine, AST, or the system-
atic inflammation marker c-reactive protein (CRP) 
(Table 3). On the other hand, among the 11 down-reg-
ulated sICPs, four (sCD80, sCD160, sCTLA-4, 
and sLAG-3) correlated inversely with MELD 
score and total bilirubin. Plasma levels of sCD80, 
sCD160, and sCTLA-4 also had negative correla-
tions with creatinine, prothrombin time, or ALT 
(Table 3). We also analyzed associations between the 
sICPs and Maddrey’s discriminant function (mDF) 
score. Soluble CD40 positively correlated (r  =  0.30, 
taBle 3. CoRRelations oF soluBle iCps WitH CliniCal paRameteRs, inFlammatoRy 
CytoKines, anD mmps in patients WitH aH
Variable
Up-Regulated Soluble ICPs Down-Regulated Soluble ICPs
CD27 CD40 HVEM TIM-3 TLR-2 CD80 CD160 CTLA-4 LAG-3
Clinical 
parameters
MELD score 0.29* 0.42‡ 0.36† 0.27* 0.23* –0.33† –0.35† –0.31† –0.25*
Total Bilirubin 0.44‡ 0.43‡ 0.36‡ –0.36† –0.28* –0.29† –0.37†
Creatinine 0.43‡ 0.62‡ 0.42‡ 0.29* –0.32†
INR –0.46‡ –0.25*
AST 0.25* 0.27*
ALT 0.27*
CRP 0.38† 0.45‡ 0.41‡ 0.28*
mDF score 0.30† –0.40† –0.25*
BT markers LBP –0.25*
LPS 0.29* 0.23* –0.42†
CD14 0.32* 0.27*
CD163 0.45‡ 0.33† 0.34† 0.36† –0.28*
Cytokines/
chemokines
IL-4
IL-6 –0.25*
IL-7 –0.32* 0.3*
IL-8 0.28* 0.51‡ 0.48‡ 0.42‡ 0.31* –0.26* –0.34*
IL-9
IL-10
IL-15 –0.25*
IP10 0.28* 0.34†
TGF-α 0.32*
TNF-α –0.32*
MMPs MMP1 0.27* –0.31*
MMP2 0.41‡ –0.31*
MMP7 0.28* 0.57‡ 0.44‡ 0.31* –0.26* –0.32*
MMP9
MMP10 0.33† 0.39†
The numbers represent Spearman’s coefficients. Negative numbers represent negative correlations.
*P < 0.05.
†P < 0.01.
‡P < 0.001.
Abbreviations: AH, alcoholic hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BT, bacterial translocation; CRP, 
c-reactive protein; ICPs, immune checkpoints; INR, international normalized ratio for prothrombin time; IP10, interferon-gamma in-
ducible protein 10; LBP, LPS-binding protein; MDC, macrophage-derived chemokine; mDF, Maddrey’s discriminant function; MELD, 
model for end-stage liver disease; MMPs, matrix metalloproteinases; TGF, transforming growth factor; TIMPs, tissue inhibitors of 
metalloproteinases.
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P  =  0.007) whereas sCD160 (r  =  −0.40, P  =  0.001) 
and sCTLA-4 (r  =  −0.25, P  =  0.03) negatively cor-
related with mDF score.
We next compared baseline plasma levels of the 18 
sICPs in patients with AH who died versus survivors. 
The nonsurvivors had higher levels of sCD27 and 
sCD40 and a lower level of sGITRL compared with 
survivors (Supporting Fig. S2A-C). In addition, sBTLA 
was detected in a higher portion of patients with AH 
who survived in comparison with the nonsurvivors 
(Supporting Fig. S2D). Next, we performed Cox regres-
sion for survival analysis to determine whether any of the 
sICPs were associated with 90-day mortality (Supporting 
Table S3). Univariate analysis revealed that sCD40, 
sCD28, mDF, and MELD scores and CRP were sig-
nificantly associated with 90-day mortality. Multivariate 
analysis indicated that a high sCD40 level and low levels 
of sCD28 and sCD160 could predict 90-day mortality 
independently of the clinical parameters and therefore 
might serve as a prognostic marker for AH.
We then determined the effect of prednisone/ 
pentoxifylline treatment on sICP expression in 
patients with AH (Supporting Table S4). The 
majority of sICPs were similarly expressed between 
the treated and untreated patients at recruitment. 
However, among the six up-regulated sICPs, sTIM-3 
and sCD40 levels were significantly higher whereas 
the down-regulated sGITR, sGITRL, and sCD160 
were significantly lower in treated patients. The 
heightened dysregulation was associated with greater 
disease severity in treated patients. At 6-month follow- 
up, levels of the up-regulated sICPs (sTIM-3, 
sHVEM, and sCD27) were higher in treated patients 
with AH. At 12-month follow-up, there were no 
differences in sICP levels between the treated and 
untreated patients with AH who were abstinent. Our 
data suggest that steroids/pentoxifylline treatment did 
not appear to have long-term immunologic benefits.
CoRRelations BetWeen 
plasma leVels oF soluBle 
iCps anD BaCteRial 
tRansloCation maRKeRs anD 
mmps in patients WitH aH
Plasma levels of LPS and several other markers that 
are associated with bacterial translocation, including 
LBP, sCD14, and sCD163, are shown in Supporting 
Tables S5 and S6. Baseline LPS, LBP, sCD14, and 
sCD163 levels were all elevated in patients with AH in 
comparison to HDCs and HCs. At follow-up, levels of 
those markers greatly decreased from the baseline val-
ues in patients with AH while remaining unchanged in 
HDCs, but sCD163 level remained higher in patients 
with AH, suggesting that other persistent inflammatory 
factors, such as TNF-α,(19) might play a role in driv-
ing sCD163 abnormalities at follow-up.(20) We next 
determined their correlations with the nine sICPs that 
were associated with liver-disease severity. LPS levels 
had positive correlations with sCD27 and sCD40 and 
negative correlations with sCD160. Plasma sCD14 
level positively correlated with sHVEM and sTIM-3, 
and sCD163 showed positive correlations with sCD40, 
sHVEM, sTIM-3, and sTLR-2 and a negative correla-
tion with sCD160 (Table 3).
Cytokines are known to regulate expression of 
ICPs, such as HVEM, PD-1, and TIM-3.(21) We 
therefore calculated the correlations between levels 
of 10 cytokines/chemokines that are up-regulated in 
patients with AH(19) with the nine sICPs (Table 3). 
Only IL-8 exhibited strong positive correlations with 
all five up-regulated sICPs and inverse correlations 
with sCD80 and sCD160. IFN-γ inducible protein 
10 (IP10) and transforming growth factor alpha 
(TGF-α) also had correlations with sTIM-3 and/or 
sTLR-2, while IL-7 had a negative correlation with 
up-regulated TLR-2 and a positive correlation with 
the down-regulated sCD160.
MMPs mediate shedding of extracellular domains 
of membrane ICPs.(22) We quantified plasma lev-
els of five major MMPs (MMP1, MMP2, MMP7, 
MMP9, and MMP10) (Supporting Tables S3 and S4). 
Compared to HCs and HDCs, patients with AH 
had significantly higher baseline levels of MMP1, 
MMP2, MMP7, and MMP10. In addition, patients 
with AH had a higher level of MMP9 than HCs. At 
follow-up, levels of MMP1 and MMP9 were similar 
between patients with AH and HDCs; however, lev-
els of MMP2, MMP7, and MMP10 remained elevated 
in patients with AH. To determine whether these up- 
regulated MMPs might be involved in sICP produc-
tion, we analyzed correlations between baseline levels 
of MMPs and sICPs in patients with AH. As shown 
in Table 3, sCD27, sCD40, sHVEM, and sTLR-2 
strongly correlated with MMP7, whereas sTIM-3 had 
a good correlation with MMP2. Additionally, MMP1 
and MMP10 also correlated with sHVEM, sCD27, or 
sCD40. Together, our data indicated that nine of the 17 
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dysregulated sICPs correlated with disease severity and 
markers of bacterial translocation. Highly up-regulated 
IL-8 and multiple MMPs, especially MMP7, were 
linked to dysregulation of sICPs in patients with AH.
DysRegulation in soluBle 
iCps Was not Fully ReVeRseD 
in patients WitH aH By 
alCoHol aBstinenCe
To determine the impact of alcohol abstinence 
on recovery of sICP abnormalities, we performed 
cross-sectional analysis on follow-up samples between 
abstinent patients with AH and HDCs. As shown in 
Table 4, all 11 down-regulated sICPs became similarly 
expressed in patients with AH and HDCs at follow- 
up. In contrast, four of the six up-regulated sICPs 
(sCD27, sCD40, sHVEM, and sTIM-3) remained 
elevated in patients with AH. Next, we performed lon-
gitudinal analysis of sICP levels in patients with AH 
and HDCs who were completely abstinent at follow- 
up. None of the six up-regulated sICPs in patients 
with AH showed significant reduction throughout 
the study, although patients with higher baseline lev-
els tended to have decreased production (Supporting 
Fig. S3A; data not shown). In contrast, four of the 
11 down-regulated sICPs (sBTLA, sCD160, sCD28, 
and sPD-L1) were significantly increased at 6-month or 
12-month follow-up (Supporting Figs. S3B,C and S4). 
For HDCs, the 18 sICPs did not show significant 
changes throughout the study (Supporting Figs. S3 
and S4; data not shown). Taken together, our data 
indicate that the dysregulated sICPs recovered greatly 
but not completely in abstinent patients with AH.
DysRegulateD memBRane iCps 
in patients WitH aH
To determine whether the dysregulated plasma sICPs 
were linked to expression of mICPs, we compared 
expression levels of the membrane-bound counterparts 
of PD-1, eight ICPs that were associated with liver 
damage of patients with AH, and LIGHT on peripheral 
blood antigen-presenting cells (APCs; such as mono-
cytes and B cells) and lymphocytes (CD4, CD8, NK, 
and natural killer T [NKT] cells) from patients with 
AH versus HCs. The mICPs were grouped as inhib-
itory/exhaustion (CTLA-4, LAG-3, PD-1, and TIM-
3), stimulatory (CD27 and CD40), and the HVEM 
axis (HVEM, BTLA, CD160, and LIGHT). Results 
are summarized in Table 5. The four major inhibitory 
ICPs (CTLA-4, LAG-3, PD-1, and TIM-3) were all 
up-regulated on CD4 T cells from patients with AH. 
Expression of LAG-3 and TIM-3 were also increased 
on CD8 T cells and NKT cells. The expression pattern 
of those inhibitory mICPs on APCs was more com-
plicated. CTLA-4 and LAG-3 were up-regulated on 
monocytes of patients with AH, while PD-1 and TIM-3 
were down-regulated on monocytes. CTLA-4 was also 
down-regulated on B cells from patients with AH. As 
to the stimulatory mICPs, CD27 was down-regulated 
on CD4 T cells while CD40 was also down-regulated 
on B cells in patients with AH. The bifunctional 
HVEM was up-regulated on all lymphocyte subsets but 
down-regulated on APCs (Table 5; Supporting Table 
S7; Supporting Fig. S5) in patients with AH. BTLA 
was down-regulated on B cells but up-regulated on 
monocytes and NK cells. CD160 was expressed less on 
NK cells and B cells. LIGHT was similarly expressed 
between patients with AH and HCs. Thus, the expres-
sion pattern of membrane forms of the HVEM axis and 
other ICPs on the surface of peripheral blood cells was 
complex. T cells mainly up-regulated inhibitory ICPs, 
whereas monocytes and B cells down-regulated several 
ICPs, suggesting that plasma sICPs, including sHVEM, 
might mainly be derived from shedding of their mem-
brane counterparts from APCs in patients with AH.
mmp-DepenDent sHeDDing oF 
HVem FRom monoCytes
To explore the mechanisms of HVEM dysreg-
ulation on APCs in patients with AH, we treated 
PBMCs from HCs with LPS in the presence and 
absence of ethanol. Both LPS and ethanol were able 
to down-regulate HVEM expression on the surface of 
monocytes (Fig. 1A) but did not alter HVEM expres-
sion on B cells (Fig. 1B). Next, we examined whether 
MMPs were involved in LPS- and ethanol-induced 
down-regulation of mHVEM on monocytes. Mono-
cytes from HCs were treated with LPS with or without 
ethanol in the presence of the broad-spectrum MMP 
inhibitor GM6001 or DMSO. GM6001 markedly 
reversed LPS-induced down-regulation of mHVEM 
(Fig. 1C) and up-regulation of sHVEM (Fig. 1D). 
These data suggest that shedding of HVEM from 
monocytes could contribute to accumulation of circu-
latory sHVEM in patients with AH.
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eFFeCt oF soluBle HVem on 
t-Cell FunCtions
To examine the function of sHVEM in AH, we 
assessed the effect of HVEM-his on cytokine pro-
duction by T cells in PBMCs from patients with AH 
versus HCs in response to T-cell receptor (TCR) 
stimulation with anti-CD3/anti-CD28 antibodies. 
HVEM-his consists of the soluble extracellular domain 
of human HVEM linked to a polyhistidine  tag  at 
the C-terminus. HVEM-his significantly inhibited 
TCR-induced TNF-α production by CD4 T cells from 
patients with AH and HCs (Fig. 2A,C). HVEM-his 
also inhibited TNF-α production by CD8 T cells from 
8 out of the 9 patients with AH, although the differ-
ence did not reach significance (Fig. 2B,D). HVEM-
his did not significantly impact IFN-γ production by 
T cells from patients with AH or HCs (Fig. 2).
Soluble proteins are often manufactured as 
Fc-fusion proteins due to the additional beneficial 
biological and pharmacologic properties of the immu-
noglobulin Fc domain, such as its ability to bind to the 
Fc receptors on immune cells. We next assessed the 
effect of HVEM-Fc, which is composed of the extra-
cellular domain of HVEM linked to the Fc region of 
a human IgG1, on TCR-induced cytokine production. 
In contrast to HVEM-his, HVEM-Fc significantly 
enhanced TNF-α production by CD4 and CD8 T 
Fig. 1. Effects of LPS, ethanol, and MMP on the productions of soluble and membrane forms of ICPs from peripheral immune cells. 
Box-and-whisker graphs showing expression of mHVEM on (A) monocytes and (B) B cells. (C) HVEM expression on monocytes and 
(D) concentrations of sHVEM in cell-free supernatant. Purified monocytes of PBMCs from 4 HCs were pretreated with GM6001 
or DMSO before incubation with LPS in the presence or absence of ethanol. Repeated measures analysis of variance test followed by 
Dunnett’s test was used to compare differences between the medium group and other in vitro treatment groups. Paired t test was used to 
calculate differences between the DMSO and GM6001 groups. *P < 0.05, **P < 0.01, ***P < 0.001. Graphs show interquartile range (box), 
median (vertical line), and outliers (whiskers). Abbreviations: EtOH, ethanol; Med, medium; MFI, mean fluorescence intensity.
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cells from patients with AH and HCs (Fig. 3A-D). 
Interestingly, HVEM-Fc significantly enhanced IFN-γ 
production by both CD4 and CD8 T cells from HCs 
but not from patients with AH (Fig. 3C,D), suggest-
ing T cells from patients with AH are dysfunctional. 
Together, our data suggest that sHVEM plays an 
inhibitory role in HVEM network-mediated TNF-α 
production and that HVEM-Fc likely acts as a mem-
brane form through its interaction with the Fc recep-
tors on monocytes, B cells, and NK cells to enhance 
T-cell function either directly or indirectly.
Discussion
In this study, we systematically profiled 18 sICPs in 
the plasma samples from a large cohort of patients with 
AH, HDCs, and HCs. In line with profound immune 
dysregulation in patients with AH,(3,19) we found that 
17 out of 18 sICPs examined here were dysregulated 
(six up-regulated and 11 down-regulated). A previous 
study found that the TIM-3 ligand galectin-9 was ele-
vated in patients with AH.(6) Here, we identified six 
additional sICPs (sCD27, sCD40, sHVEM, sLIGHT, 
Fig. 2. Effect of HVEM-his on TNF-α and IFN-γ production by T cells from patients with AH and HCs. In A, B the box and number 
represent gate and percentage of cytokine positive T cells. In C,D each line shows data from an individual donor. (A,B) Representative 
plots and (C,D) summary graphs  showing the effect of HVEM-his on cytokine production by (A,C) CD4 and (B,D) CD8 T cells from 
patients with (A-D) AH and (C,D) HCs. PBMCs were pretreated with HVEM-his or PBS and stimulated with soluble anti-CD3/ 
anti-CD28 antibodies (n = 9). Paired t test was performed to compare TNF-α or IFN-γ expression between HVEM-his and PBS control; 
*P < 0.05, **P < 0.01. 
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sTIM-3, and sTLR-2) that were up-regulated in the 
blood of patients with AH. Interestingly, these six 
sICPs have been shown to be cleaved from membrane 
counterparts by sheddases.(23-25) Consistent with 
shedding for the generation of these sICPs, we found 
that membrane forms of CD27, CD40, HVEM, and 
TIM-3 were down-regulated on the surface of subsets 
of blood immune cells in patients with AH.
We found that multiple MMPs, especially MMP7, 
were greatly elevated in patients with AH. In addi-
tion, MMP7 positively correlated with plasma levels 
of sCD27, sCD40, sHVEM, and sTLR-2, whereas 
MMP2 levels correlated with sTIM-3 levels in 
patients with AH, suggesting that they are involved 
in dysregulation of both soluble and membrane ICPs. 
It is possible that other sheddases also contributed to 
the cleavage of these molecules. MMP expression and 
activities are often enhanced by inflammatory cyto-
kines, including IL-8,(26) which is one of the most 
highly up-regulated inflammatory cytokines in patients 
with AH and is associated with disease severity.(19,27) 
Plasma levels of IL-8 and MMP7/MMP2 correlated 
with levels of sCD27, sCD40, sHVEM, sTIM-3, and 
sTLR-2, suggesting that IL-8 might contribute to 
production of these sICPs through up-regulation of 
MMPs. Future study is warranted to verify this link.
Strikingly, 11 out of the 18 sICPs examined here 
were down-regulated in patients with AH. Most of 
the 11 sICPs, including four inhibitory ICPs (BTLA, 
CTLA-4, LAG-3, and PD-1) and three stimulatory 
Fig. 3. Effect of HVEM-Fc on production of TNF-α and IFN-γ by T cells from patients with AH and HCs. In A, B the box and number 
represent gate and percentage of cytokine positive T cells. In C,D each line shows data from an individual donor. (A,B) Representative 
plots and (C,D) summary graphs  showing the effect of recombinant HVEM-Fc on production of TNF-α and/or IFN-γ by (A,C) CD4 
and (B, D) CD8 T cells from patients with (A-D) AH and (C,D) HCs. PBMCs from patients with AH or HCs were pretreated with 
HVEM-Fc or human IgG1 isotype control and stimulated with anti-CD3/anti-CD28 antibodies (n = 10). Paired t test was performed to 
compare TNF-α or IFN-γ expression between HVEM-Fc and hIgG1 control; *P < 0.05, **P < 0.01. Abbreviation: hIgG1, human IgG1 
isotype control. 
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ICPs (GITR, CD80, and ICOS), are generated through 
mRNA alternative splicing and secretion,(16,28,29) 
whereas sCD28, sCD160, sPD-L1 are cleaved from 
membrane-bound counterparts.(23-25) Consistent with 
their hyperactivated state, T cells from patients with 
AH expressed high levels of membrane-bound inhib-
itory ICPs, including CTLA4, LAG-3 and PD-1. 
Thus, decreased production of sCTLA-4, sLAG-3, 
and sPD-1 contrasted with up-regulated expression 
of their membrane counterparts on T cells in patients 
with AH. The discorded expression of soluble versus 
membrane forms of CTLA-4 is in line with a previ-
ous study.(18) Alternatively spliced transcripts encoding 
sCTLA-4 are the predominant CTLA-4 transcripts 
in human resting T cells.(18) Following T-cell activa-
tion, full-length CTLA-4 transcripts encoding mem-
brane CTLA-4 increase while sCTLA-4 transcripts 
decrease.(18) On the other hand, T-cell activation leads 
to a parallel increase in the expression of full-length 
PD-1 and sPD-1 transcripts.(28) Future analysis of 
the origin of sICPs in patients with AH will pro-
vide a better insight into mechanisms associated with 
their biosynthesis. The clinical significance of down- 
regulation of sICPs needs further study.
Alcohol abstinence significantly improves disease 
outcome and survival but does not lead to complete 
recovery in most patients with AH.(30) Consistent 
with this, we have recently reported that plasma levels 
of IL-8 and TNF-α are not normalized in abstinent 
patients with AH.(19) Here, we identified four addi-
tional sICPs (sCD27, sCD40, sHVEM, and sTIM3) 
that were not fully reversed in abstinent patients with 
AH. Our results suggest that these sICPs could serve 
as sensitive markers for persistent immune activation 
in abstinent patients with AH. Strikingly, sCD27 and 
sCD40 levels were significantly higher in the deceased 
compared to the survivors. Elevated sCD40 in several 
liver diseases correlates with liver injury(31) and could 
be used to detect liver injury in patients with chronic 
hepatitis B infection.(32) Here, we also found that 
sCD40 could independently predict 90-day mortality.
HVEM controls both inflammatory and inhibitory 
responses through its complex interactions with mul-
tiple stimulatory ligands and inhibitory receptors and 
bidirectional signaling.(8,33) Unlike many other ICPs, 
mHVEM is constitutively expressed on immune cells 
and nonhematopoietic cells.(7) HVEM also exists as 
a soluble form in the circulation.(34) Preclinical and 
clinical studies have suggested that dysregulation of 
the HVEM network contributes to multiple inflam-
matory and infectious diseases.(33,35-37) Currently, 
the expression pattern and roles of the HVEM axis 
in AH pathogenesis are unknown. Here, we found 
that expression of both soluble and membrane forms 
of the HVEM network were highly dysregulated 
in patients with AH. Soluble HVEM was among 
the highly up-regulated sICPs in patients with AH. 
Studies have shown that circulating sHVEM is ele-
vated in several allergic and autoimmune diseases(17,34) 
and in patients with hepatocellular carcinoma.(38) 
We also found that mHVEM expression was down- 
regulated on B cells and monocytes, suggesting those 
cells might be a source of sHVEM. A previous study 
found that patients with gastric cancer expressed less 
HVEM on leukocytes, including monocytes, and had 
higher levels of sHVEM.(17) HVEM can be cleaved in 
an MMP-dependent manner from human monocytes 
following stimulation by IL-8, TNF-α, and LPS.(17) 
Consistent with this, we found that LPS and ethanol 
reduced mHVEM expression and increased sHVEM 
in an MMP-dependent manner, suggesting that 
HVEM shedding from monocytes could contribute 
to sHVEM elevation in patients with AH. We also 
detected mHVEM on multiple human liver cell lines, 
including HepG2 and Hu7 hepatocytes (data not 
shown). Future study is needed to investigate whether 
mHVEM and sHVEM expression by these cells are 
affected by ethanol and/or inflammatory factors.
Our ex vivo study revealed that sHVEM inhib-
ited TNF-α production by T cells from patients with 
AH and HCs. Although it is not clear how sHVEM 
mediated this effect, it is possible that HVEM-his 
interrupted the engagement of mHVEM on T cells 
by LIGHT on monocytes or neighboring activated 
T cells to down-regulate HVEM-mediated T-cell 
costimulatory signaling.(7,39) Alternatively, sHVEM 
could act as an agonist to activate the inhibitory 
receptors BTLA/CD160 on T cells.(7) Although 
clinical and experimental studies have shown that 
TNF-α contributes to AH pathogenesis, TNF-α 
neutralization in clinical trials failed to show any 
benefits for treatment of AH(40,41) and was actually 
associated with significantly higher rates of infec-
tions and mortality.(40,41) This is consistent with the 
notion that TNF-α plays a critical role in antimi-
crobial defense. Thus, sHVEM dysregulation might 
contribute to enhanced susceptibility to infections 
in patients with AH. HVEM-Fc might be used to 
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reverse this defect in cytokine production by T cells 
through its binding to Fc receptors on immune cells, 
including APC, and acting as a membrane form to 
interact with its binding partners, such as LIGHT, 
on T cells.(7,8) As HVEM and its binding partners 
are expressed on different types of cells, sHVEM 
likely impacts the function of those cells in patients 
with AH. Future studies are needed to elucidate the 
mechanisms of action for sHVEM and the interplay 
between various soluble and membrane ICPs, includ-
ing the HVEM axis. Furthermore, mechanistic stud-
ies using mice deficient of genes in the HVEM axis 
or by treatment with neutralizing antibodies will help 
to dissect the role of the HVEM pathways in AH 
pathogenesis.
In conclusion, we found that patients with AH 
had a broad dysregulation of sICPs in the peripheral 
circulation and that cessation of alcohol consumption 
greatly but not completely reversed these abnormali-
ties. As circulatory sICP levels can be easily measured, 
they can be further explored as potential prognostic 
and/or predictive markers for AH. Development of 
therapies to target those dysregulated ICPs, including 
HVEM, may represent a potential strategy for restor-
ing immune homeostasis and antimicrobial defense in 
patients with AH.
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